R&D Centers

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

Biological Antibody Technology

PHM-TPD Platform

Innovative Medical Technology

R&D Center in the U.S.

Key R&D Capabilities

International R&D Collaboration

Exploratory Study for Innovative Drugs

Innovative Medical Technology

 

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Platforms and Technologies

PHM-TPD & Novel Drug Delivery Systems

Novel Drug Delivery Systems:

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

PHM-TPD & Novel Drug Delivery Systems

PHM-TPD platform:

PHM-TPD platform based on targeted protein degradation; key procedure establishment for targets discovery, drug design and synthesis, biological screening and evaluation;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology:

Significant improvement of efficiency and speed in antibody development, effective screening of antibody candidates;

Antibodies

Bispecific T-cell Engager Technology:

High affinity binding to tumor targets (better efficacy), low affinity binding to T-cells (lower toxicity), a wider therapeutic window;

Antibodies

Antibody Drug Conjugate Technology:

Efficient screening of high-quality antibodies for ADC(Antibody Drug Conjugate);

Antibodies

Nanobody Platform:

Efficient screening, evaluation and manufacturing process development have ensured the druggability of nanobodies;

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy :

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

CAR-T Cell Immunotherapy:

Developed next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Key Laboratory

The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of:

Long-acting drug delivery system and drug release technology

Targeting drug delivery system and drug release technology

High-end carrier materials for long-acting and targeting drug delivery

3R&D Centers

located in China, the United States
and Europe

Robust R&D pipelines of drug candidates:

30+ in China

10+ overseas

Over 900 R&D professionals

R&D Centers

R&D Center in the U.S.

Key R&D Capabilities

Exploratory Study for Innovative Drugs

International R&D Collaboration

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

Biological Antibody Technology

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Platforms and Technologies

PHM-TPD & Novel Drug Delivery Systems

Novel Drug Delivery Systems:

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

PHM-TPD & Novel Drug Delivery Systems

PHM-TPD platform:

PHM-TPD platform based on targeted protein degradation; key procedure establishment for targets discovery, drug design and synthesis, biological screening and evaluation;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology:

Significant improvement of efficiency and speed in antibody development, effective screening of antibody candidates;

Antibodies

Bispecific T-cell Engager Technology:

High affinity binding to tumor targets (better efficacy), low affinity binding to T-cells (lower toxicity), a wider therapeutic window;

Antibodies

Antibody Drug Conjugate Technology:

Efficient screening of high-quality antibodies for ADC(Antibody Drug Conjugate);

Antibodies

Nanobody Platform:

Efficient screening, evaluation and manufacturing process development have ensured the druggability of nanobodies;

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy :

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

CAR-T Cell Immunotherapy:

Developed next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Overseas R&D Pipelines
R&D Pipelines in China

Key Laboratory

The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of:

Long-acting drug delivery system and drug release technology

Targeting drug delivery system and drug release technology

High-end carrier materials for long-acting and targeting drug delivery